Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38753448/
ClinicalTrials.gov identifier: NCT03814187.
The ORION-8 study demonstrated that long-term inclisiran use consistently lowered LDL-C by 49.4% with 78.4% achieving LDL-C goals, showing favorable safety and tolerability over 12,000+ patient-years exposure.
Share
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39136871/
Atherosclerotic cardiovascular disease (ASCVD), a leading cause of mortality and morbidity, is associated with a substantial healthcare and economic burden. Reduction of low-density lipoprotein cholesterol (LDL-C) to guideline-recommended goals is...
Inclisiran, a novel LDL-C lowering therapy, offers biannual HCP-administered in-office dosing via the buy-and-bill model, potentially improving ASCVD management by enhancing adherence, timely care, and cardiovascular outcomes.
Share
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38592091/
Atherosclerotic cardiovascular disease (ASCVD) represents a major global health challenge, significantly contributing to mortality rates. This chronic inflammatory condition affecting blood vessels is intricately linked to hypercholesterolemia, with elevated levels...
Atherosclerotic cardiovascular disease, driven by hypercholesterolemia, benefits from lipid-lowering therapies. Novel agents like PCSK9 inhibitors and bempedoic acid enhance LDL-C management, addressing statin limitations and advancing cardiovascular risk reduction strategies.
Share
Characteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39275243/
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD). During pregnancy, physiological changes elevate cholesterol and triglyceride levels to support fetal development, which can exacerbate pre-existing conditions and...
Dyslipidemia during pregnancy increases ASCVD risk and complications. Management, including dietary adjustments and selective pharmacological interventions, requires a personalized, multidisciplinary approach to balance maternal and fetal health, especially in inherited dyslipidemia.
Share
Therapeutic potential of adiponectin in prediabetes: strategies, challenges, and future directions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38250316/
Adiponectin, an adipose-derived hormone, plays a pivotal role in glucose regulation and lipid metabolism, with a decrease in circulating adiponectin levels being linked to insulin resistance and prediabetes. This review...
This review explores adiponectin's role in glucose regulation, insulin sensitivity, and lipid metabolism, highlighting strategies to boost its levels for managing prediabetes, and addressing challenges in clinical translation.
Share